GlassScriptPhysician profile
Samuel Russell
NPI 1043978844
$3,049.77
in general payments reported to CMS, 2019-2025
25 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $529 · 2023: $441 · 2024: $829 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.80 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $503.20 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $257.15 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $229.54 | 2024-2025 | Auvelity, Sunosi, Symbravo |
| Otsuka America Pharmaceutical, INC. | $166.71 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $157.38 | 2022-2025 | Trintellix |
| Lilly USA, LLC | $141.69 | 2022-2025 | Mounjaro, Reyvow, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.76 | 2022-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.41 | 2024-2025 | Caplyta |
| Pfizer INC. | $104.36 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $78.00 | 2024-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $55.16 | 2022-2025 | |
| Corcept Therapeutics | $44.73 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $30.94 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $30.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $26.84 | 2025 | Senza |
| Lundbeck LLC | $23.67 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $23.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.71 | 2023 | Seglentis |
| Inspire Medical Systems, INC. | $20.70 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $20.10 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $19.66 | 2025 | Gvoke Hypopen |
| Smith+Nephew, INC. | $15.62 | 2024 | Collagenase Santyl |
| Nevro Corp. | $14.13 | 2023 | Senza |
| Ibsa Pharma INC. | $14.07 | 2024 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.